FDA 483 - Xiamen LP Pharmaceutical Co., Ltd. - March 04, 2022

Xiamen LP Pharmaceutical Co., Ltd, a drug manufacturer in Xiamen, China, received two observations during an FDA inspection. The firm was cited for failing to follow its written procedures for equipment calibration and for having a deficient supplier management program. These issues indicate a lack of adherence to established quality control practices for manufacturing and supplier oversight.